DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26Zacks Investment Research • 08/12/25
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 08/11/25
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)GlobeNewsWire • 07/07/25
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?Zacks Investment Research • 06/05/25
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in FocusZacks Investment Research • 05/07/25
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter SyndromeGlobeNewsWire • 05/06/25
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock UpZacks Investment Research • 04/03/25
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START ProgramGlobeNewsWire • 04/02/25
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsGlobeNewsWire • 02/27/25
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp AlfaGlobeNewsWire • 02/06/25
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy DesignationZacks Investment Research • 01/09/25
Denali Reverses Its Fortunes With 'Too Early' Miss In ALS TreatmentInvestors Business Daily • 01/07/25
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialGlobeNewsWire • 01/06/25